Cargando…

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

BACKGROUND: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC). PATIENTS AND METHODS: Medical records and follow-up...

Descripción completa

Detalles Bibliográficos
Autores principales: Glajzer, Jacek, Castillo-Tong, Dan Cacsire, Richter, Rolf, Vergote, Ignace, Kulbe, Hagen, Vanderstichele, Adriaan, Ruscito, Ilary, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Gourley, Charlie, Gabra, Hani, Taube, Eliane T., Dorigo, Oliver, Horst, David, Keunecke, Carlotta, Baum, Joanna, Angelotti, Timothy, Sehouli, Jalid, Braicu, Elena Ioana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726811/
https://www.ncbi.nlm.nih.gov/pubmed/36085390
http://dx.doi.org/10.1245/s10434-022-12459-3
_version_ 1784844870817415168
author Glajzer, Jacek
Castillo-Tong, Dan Cacsire
Richter, Rolf
Vergote, Ignace
Kulbe, Hagen
Vanderstichele, Adriaan
Ruscito, Ilary
Trillsch, Fabian
Mustea, Alexander
Kreuzinger, Caroline
Gourley, Charlie
Gabra, Hani
Taube, Eliane T.
Dorigo, Oliver
Horst, David
Keunecke, Carlotta
Baum, Joanna
Angelotti, Timothy
Sehouli, Jalid
Braicu, Elena Ioana
author_facet Glajzer, Jacek
Castillo-Tong, Dan Cacsire
Richter, Rolf
Vergote, Ignace
Kulbe, Hagen
Vanderstichele, Adriaan
Ruscito, Ilary
Trillsch, Fabian
Mustea, Alexander
Kreuzinger, Caroline
Gourley, Charlie
Gabra, Hani
Taube, Eliane T.
Dorigo, Oliver
Horst, David
Keunecke, Carlotta
Baum, Joanna
Angelotti, Timothy
Sehouli, Jalid
Braicu, Elena Ioana
author_sort Glajzer, Jacek
collection PubMed
description BACKGROUND: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC). PATIENTS AND METHODS: Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups. RESULTS: Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence. CONCLUSIONS: Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC.
format Online
Article
Text
id pubmed-9726811
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-97268112022-12-08 Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium Glajzer, Jacek Castillo-Tong, Dan Cacsire Richter, Rolf Vergote, Ignace Kulbe, Hagen Vanderstichele, Adriaan Ruscito, Ilary Trillsch, Fabian Mustea, Alexander Kreuzinger, Caroline Gourley, Charlie Gabra, Hani Taube, Eliane T. Dorigo, Oliver Horst, David Keunecke, Carlotta Baum, Joanna Angelotti, Timothy Sehouli, Jalid Braicu, Elena Ioana Ann Surg Oncol Gynecologic Oncology BACKGROUND: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC). PATIENTS AND METHODS: Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups. RESULTS: Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence. CONCLUSIONS: Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC. Springer International Publishing 2022-09-09 2023 /pmc/articles/PMC9726811/ /pubmed/36085390 http://dx.doi.org/10.1245/s10434-022-12459-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gynecologic Oncology
Glajzer, Jacek
Castillo-Tong, Dan Cacsire
Richter, Rolf
Vergote, Ignace
Kulbe, Hagen
Vanderstichele, Adriaan
Ruscito, Ilary
Trillsch, Fabian
Mustea, Alexander
Kreuzinger, Caroline
Gourley, Charlie
Gabra, Hani
Taube, Eliane T.
Dorigo, Oliver
Horst, David
Keunecke, Carlotta
Baum, Joanna
Angelotti, Timothy
Sehouli, Jalid
Braicu, Elena Ioana
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
title Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
title_full Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
title_fullStr Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
title_full_unstemmed Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
title_short Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
title_sort impact of brca mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: a multicenter retrospective study by the ovarian cancer therapy-innovative models prolong survival (octips) consortium
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726811/
https://www.ncbi.nlm.nih.gov/pubmed/36085390
http://dx.doi.org/10.1245/s10434-022-12459-3
work_keys_str_mv AT glajzerjacek impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT castillotongdancacsire impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT richterrolf impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT vergoteignace impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT kulbehagen impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT vandersticheleadriaan impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT ruscitoilary impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT trillschfabian impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT musteaalexander impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT kreuzingercaroline impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT gourleycharlie impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT gabrahani impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT taubeelianet impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT dorigooliver impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT horstdavid impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT keuneckecarlotta impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT baumjoanna impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT angelottitimothy impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT sehoulijalid impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium
AT braicuelenaioana impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium